Lantern Pharma Inc (LTRN) - News Archive

: In a pivotal development for the treatment of Triple Negative Breast Cancer (TNBC), Lantern Pharma Inc. (Nasdaq: LTRN), an avant-garde artificial intelligence (AI) driven biotech company, has announced the U.S. Food a...

Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) company focused on developing targeted cancer therapies, recently announced significant progress in its clinical research initiatives. The compa...

In an inspiring development for the oncology community, Lantern Pharma Inc. (NASDAQ: LTRN), an emerging leader in targeted cancer therapies powered by artificial intelligence (AI), has announced the dosing of its first...

The battle against glioblastoma, one of the most aggressive and lethal forms of brain cancer, has seen a surge of innovative approaches in drug discovery and development. Lantern Pharma Inc. an artificial intelligence (...

Pediatric cancers, while rare, present significant challenges in terms of diagnosis and treatment. Among these, malignant rhabdoid tumors (MRT) and rhabdomyosarcoma are particularly aggressive and require urgent attenti...

Harnessing AI Innovation in Oncology: Lantern Pharma s Breakthroughs in Cancer Treatment Synergy and Development In recent developments that promise a transformative impact on oncology drug development, Lantern Pharma I...

Lantern Pharma Makes Strides in Molecular Diagnostic Development for Oncology Clinical Trials with LP-184Cancer research and drug development have witnessed remarkable advancements in recent years with the integration o...

Oregon Therapeutics & Lantern Pharma Collaborate to Drive Development of First-In-Class Cancer Drug Candidate XCE853 Using AI TechnologyParis & Dallas - Lantern Pharma Inc. (NASDAQ: LTRN), a prominent pioneer in artific...

Lantern Pharma Inc., a pioneering artificial intelligence (AI) company revolutionizing cancer therapy development, has recently unveiled an exciting webinar series known as Webinar Wednesdays. This insightful initiative...

Lantern Pharma, an AI company focused on developing innovative cancer therapies through its proprietary AI and machine learning platform, RADR, has recently made significant progress in its drug development programs. Th...

In a powerful move towards revolutionizing cancer drug discovery, Lantern Pharma Inc. (NASDAQ: LTRN) is set to participate in H.C Wainwright & Co. s 1st Annual Artificial Intelligence Based Drug Discovery & Development...

Lantern Pharma, a prominent player in AI-driven cancer drug discovery and development, recently achieved significant milestones concerning the growth, size, and progress of its proprietary AI platform called RADR. This...